Sanofi Presents Real-World Evidence at ADA: Early Combined Initiation of Insulin and GLP-1 RA Offers Superior Glycemic Control in Type 2 Diabetes

June 15, 2020 /BioonBIOON/ -- Sanofi recently in the United StatesDiabetes80th Scientific Sessions of the American Diabetes Association (ADA)ConferenceNew data from a real-world evidence study were released. The results showed that in patients with type 2 diabetes who were receiving oral antidiabetic drugs but had inadequate glycemic control,Diabetes(A1c ≥9%) In adult patients, when initiating combination therapy with insulin and a GLP-1 receptor agonist (GLP-1 RA), the probability of achieving glycemic treatment targets is significantly higher when the initiation of the two drugs is closely timed (interval ≤90 days, ideally ≤30 days) compared to when the initiation interval ranges from 3 months to 1 year.

In the same population, studies also found that initiating treatment with one insulin and one GLP-1 RA within 90 days resulted in a higher proportion of patients achieving HbA1c levels <7% or <8% at 6 and 12 months, compared with initiating the two drugs with an interval of 3 months to 1 year. In these studies, patients were required to use long-acting or intermediate-acting insulin. Detailed data are shown in the figure below (Click the image: View larger image）

This real-world evidence study utilized data from the Optum Humedica electronic health record and claims database (January 1, 2011, to June 30, 2017), a large and diverse dataset representative of the US population.

Type 2DiabetesPatients’ need for early and timely treatment remains unmet. The latest data presented at this conference indicate that initiating insulin and GLP-1 RA therapy simultaneously provides better glycemic control than sequential initiation of the two agents.

Soliqua can meet the needs of type 2DiabetesThe patient’s need to initiate both insulin and GLP-1 RA therapy simultaneously, this drug

It is a combination diabetes medication developed by Sanofi, composed of a fixed dose of basal insulin glargine (100 U/mL) and a glucagon-like peptide-1 receptor agonist (GLP-1 RA), lixisenatide (33 mcg/mL).The two agents exhibit complementary glucose-lowering efficacy. Specifically, basal insulin glargine targets fasting blood glucose, while lixisenatide targets postprandial blood glucose; both contribute to reducing glycated hemoglobin (HbA1c) levels.

Soliqua is an injectable medication administered once daily. Its indications are: (1) as an adjunct to diet and exercise for adult patients with type 2 diabetes whose glycemic control is inadequate on basal insulin or lixisenatide therapy; (2) for adult patients with type 2 diabetes whose glycemic control is inadequate on oral antidiabetic drugs.

Dr. Juan Frias, Investigator of the study and Director and Principal Investigator of the National Institute in Los Angeles, California, stated, “In my practice, due to the natural progression of diabetes being associated with advanced disease, patients with high blood glucose levels, particularly those exceeding 9%, are at a high risk of developing comorbidities. One benefit of real-world evidence is that it provides insights into the effectiveness of treatments in real-life settings. In this study, real-world data suggest that early initiation of combination therapy with insulin and GLP-1 receptor agonists (GLP-1 RAs) may offer potential benefits for patients with type 2 diabetes whose blood glucose levels are severely uncontrolled.”

Rogelio Braceras, MD, Medical Director of General Medicines at Sanofi North America, stated: “Patients with type 2 diabetes, particularly those whose blood glucose levels are 1.5–2% above target, represent a clinical challenge. The ADA treatment guidelines recommend initiating combination therapy for these patients. GLP-1 RAs and insulin have complementary effects, and the simultaneous initiation of these two classes of medications may provide an effective treatment option for adult patients with type 2 diabetes. Sanofi is committed to providing robust real-world evidence to the diabetes community to ensure that healthcare professionals and patients can make informed treatment decisions aligned with each individual’s needs.” (Bioon.com)

Original Source: ADA: Sanofi Bolsters Soliqua with Real-World Data Showing Starting Insulin and GLP-1 Together Helps Control Blood Sugar